5.62

0.88% -0.05

After Hours: 5.60 -0.02 -0.36%

Ars Pharmaceuticals Inc (SPRY)

Overview News Price History Option Chain Financials Discussions Forecast

Ars Pharmaceuticals Inc stock is traded at $5.62, with a volume of 849.46K. It is down -0.88% in the last 24 hours and up +5.64% over the past month. ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.

Previous Close:

$5.67

Open:

$5.6

24h Volume:

849.46K

Relative Volume:

0.43

Market Cap:

$558.89M

Revenue:

$98.99M

Net Income/Loss:

$-197.98M

P/E Ratio:

-2.8076

EPS:

-2.0017

Net Cash Flow:

$-175.32M

1W Performance:

-4.58%

1M Performance:

+5.64%

6M Performance:

-37.83%

1Y Performance:

-47.43%

1-Day Range:

$5.54

$5.70

1-Week Range:

$5.54

$6.09

52-Week Range:

$4.9102

$13.15

Ars Pharmaceuticals Inc Stock (SPRY) Company Profile

Name

Ars Pharmaceuticals Inc

Sector

Healthcare (1074)

Industry

Biotechnology (600)

Phone

858-771-9307

Address

11682 EL CAMINO REAL, SUITE 300, SAN DIEGO

Employee

159

Twitter

Next Earnings Date

2026-08-13

Latest SEC Filings

SPRY's Discussions on Twitter

Compare SPRY vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SPRY Ars Pharmaceuticals Inc	5.62	547.46M	98.99M	-197.98M	-175.32M	-2.0017
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-09-26	Initiated	Northland Capital	Outperform
Nov-04-25	Resumed	Roth Capital	Buy
Sep-04-25	Initiated	Roth Capital	Buy
Mar-07-25	Initiated	Scotiabank	Sector Outperform
Feb-10-25	Initiated	Oppenheimer	Outperform
Aug-20-24	Initiated	Cantor Fitzgerald	Overweight
Aug-13-24	Upgrade	Raymond James	Outperform → Strong Buy
Aug-12-24	Reiterated	Leerink Partners	Outperform
Jul-25-24	Initiated	Raymond James	Outperform
Mar-05-24	Upgrade	Leerink Partners	Market Perform → Outperform
Feb-20-24	Upgrade	William Blair	Mkt Perform → Outperform
Sep-20-23	Downgrade	William Blair	Outperform → Mkt Perform
Jan-31-23	Initiated	Wedbush	Outperform
Jan-03-23	Initiated	William Blair	Outperform
Dec-13-22	Initiated	SVB Leerink	Outperform

View All

Ars Pharmaceuticals Inc Stock (SPRY) Latest News

01:08 AM

Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals - globenewswire.com

01:08 AM

Sep 06, 2026

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRY - GlobeNewswire Inc.

Sep 06, 2026

SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit - The Conway Daily Sun

Sep 06, 2026

Sep 05, 2026

SPRY Stock Tanks Over 23% After-Hours — ARS Pharmaceuticals Reports No New Major Insurance Wins For Neffy - Stocktwits

Sep 05, 2026

Sep 04, 2026

Another ARS Pharma (NASDAQ: SPRY) insider stock sale is coming, with the size now disclosed - Stock Titan

Sep 04, 2026

SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law - globenewswire.com

Sep 04, 2026

Sep 03, 2026

Kaplan Fox Continues to Remind ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors of the Lead Plaintiff Deadline on October 5, 2026 - newmediawire.com

Sep 03, 2026

ARS Pharmaceuticals (SPRY) insider lines up Sept. 3 stock sale after August trades - Stock Titan

Sep 03, 2026

Faruqi & Faruqi, LLP Urges ARS Pharmaceuticals (SPRY) Investors t - The National Law Review

Sep 03, 2026

Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals Inc. Investors to Act: Class Action Filed Alleging Investor Harm - WBOC TV

Sep 03, 2026

SPRY UPCOMING DEADLINE: SueWallSt Alerts ARS Pharmaceuticals Inc. Stockholders of Securities Class ActionContact the Firm - Morningstar

Sep 03, 2026

Sep 02, 2026

Insider at ARS Pharmaceuticals (NASDAQ: SPRY) plans another stock sale - Stock Titan

Sep 02, 2026

ARS Stock Drop: Robbins LLP Reminds Investors They May Be Eligible to Lead the Class Action Against ARS Pharmaceuticals Inc. - TMX Newsfile

Sep 02, 2026

SPRY Shareholder Alert: ARS Pharmaceuticals Inc. Securities Class Action LawsuitInvestors Should Contact Levi & Korsinsky - PR Newswire

Sep 02, 2026

ARS Pharmaceuticals (SPRY) Institutional Ownership 2026 $SPRY - MarketBeat

Sep 02, 2026

Sep 01, 2026

Kaplan Fox Continues to Alert Investors of a Securities Class Act - The National Law Review

Sep 01, 2026

Kaplan Fox Continues to Alert Investors of a Securities Class Action Deadline on October 5, 2026 Against ARS Pharmaceuticals Inc. (NASDAQ: SPRY) - Barchart.com

Sep 01, 2026

Repeat insider selling at ARS Pharma (SPRY) now includes a planned early-September trade - Stock Titan

Sep 01, 2026

Acurx Pharmaceuticals, Inc. SEC Filing (Sep 1, 2026) - Stock Titan

Sep 01, 2026

ARS Pharmaceuticals to Participate in Upcoming Investor Conferences - The Manila Times

Sep 01, 2026

SPRY INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review

Sep 01, 2026

Aug 31, 2026

ROSEN, REGARDED INVESTOR COUNSEL, Encourages ARS - globenewswire.com

Aug 31, 2026

ARS Pharma (NASDAQ: SPRY) insider lines up new sale after August stock disposals - Stock Titan

Aug 31, 2026

SPRY Shareholder Alert: ARS Pharmaceuticals Inc. Securities - globenewswire.com

Aug 31, 2026

SPRY CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds ARS Pharma - The National Law Review

Aug 31, 2026

Aug 28, 2026

ROSEN, NATIONAL TRIAL LAWYERS, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel ... - Herald and News

Aug 28, 2026

Aug 27, 2026

Kaplan Fox Continues to Alert Investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) to a Class Action Deadline on October 5, 2026 - Barchart.com

Aug 27, 2026

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming DeadlinesSPRY - PR Newswire

Aug 27, 2026

ARS PHARMACEUTICALS ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire

Aug 27, 2026

SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in ARS Pharmaceuticals Inc. LawsuitSPRY - Morningstar

Aug 27, 2026

Kaplan Fox Encourages ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Inv - The National Law Review

Aug 27, 2026

Aug 26, 2026

Levi & Korsinsky Reminds ARS Pharmaceuticals Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 5, 2026SPRY - PR Newswire

Aug 26, 2026

Aug 25, 2026

ROSEN, NATIONAL TRIAL COUNSEL, Encourages ARS - globenewswire.com

Aug 25, 2026

SPRY INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ARS Pharmaceuticals Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Aug 25, 2026

Important Notice to Long-Term Shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY); Hub ... - Herald and News

Aug 25, 2026

Kaplan Fox Encourages ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors Seeking Recovery to Contact the Firm Before October 5, 2026 - Barchart.com

Aug 25, 2026

Aug 21, 2026

ARS Pharma (SPRY) Cuts Spending As It Chases Neffy Market Share - Yahoo Finance

Aug 21, 2026

SPRY Investors Have Rights – If You Lost Money Investing in - GlobeNewswire

Aug 21, 2026